Info

Flux

Flux is a podcast about the pioneers building companies at the frontier of technology. This series of interviews goes beyond the soundbites, allowing some of the most interesting players in technology to share their insider expertise and explain the challenges they face in building the future.
RSS Feed
Flux
2021
June


2020
December
October
June
February


2019
September
August
January


2018
November
October
September
July


2017
December
July
May
April
March
February
January


All Episodes
Archives
Now displaying: August, 2019
Aug 23, 2019

In this episode I talk with Matt Cauble the co-founder of Kin Euphorics, a functional beverage company that aims to reduce stress — “all bliss, no booze.” Matt was previously a co-founder of Soylent and he shares tales from the company’s early days, describing how they made one of the largest pivots in YC history from building software-defined radios to meal-replacement shakes. He explains why Soylent resonated and we get into co-founder Rob Rhinehart's latest interest in space settlement and the Mars industry event he hosted in the Mojave. Matt shares why he is now interested in wellness, how he's applying lessons from Soylent to building the Kin community, and why strong companies often look like new social movements. We get into the product’s formula, which includes nootropics and adaptogens, and what it means to challenge a ritual as ancient as alcohol.

Aug 15, 2019
Eric Marcotulli is the co-founder of Elysium, a life sciences company developing consumer-facing health products based on aging research. Elysium's first product is Basis, a supplement that increases NAD levels and activates sirtuins, boosting cellular health and longevity. 
 
In the latest episode of Flux we discuss why longevity companies like Sirtris Pharmaceuticals failed, which was initially bought for $720 million in 2008. Eric explains why going direct to consumer is the best strategy and what the current Basis user base looks like. He shares what its like working with eight nobel laureates on his science advisory board and how they decide what product research to pursue. He gets into the importance of bringing peer review rigor to the category, how he plans to build consumer trust, why cellular senescence is a particular area of interest, what his personal health routine is and how he thinks about the singularity. 
1